バイオシミラーの世界市場予測(~2027年)

• 英文タイトル:Biosimilars Market Research Report by Indication, Product, Manufacturing, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19

Biosimilars Market Research Report by Indication, Product, Manufacturing, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19「バイオシミラーの世界市場予測(~2027年)」(市場規模、市場予測)調査レポートです。• レポートコード:MRC2301G186
• 出版社/出版日:360iResearch / 2022年10月
• レポート形態:英語、PDF、221ページ
• 納品方法:Eメール(受注後2-3日)
• 産業分類:医療
• 販売価格(消費税別)
  Single User(1名利用、印刷可)¥742,350 (USD4,949)▷ お問い合わせ
  Enterprise License(企業利用、印刷可)¥1,492,350 (USD9,949)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
360iResearch社の本調査資料では、2021年に120.6億ドルであった世界のバイオシミラー市場規模が、2022年に149.6億ドルまで達し、2027年まで年平均24.18%で成長して442.7億ドルに拡大すると推測しています。本資料は、バイオシミラーの世界市場について調査・分析を行い、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、適応症別(自己免疫疾患、血液疾患、慢性疾患、成長ホルモン欠乏症、その他)分析、製品別(組換えグリコシル化タンパク質、組換えペプチド)分析、製造別(受託製造、自社製造)分析、地域別(南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他)分析、競争状況、企業情報などを整理しています。本資料には、AMEGA Biotech S.A.、Amgen Inc.、Apotex Inc.、Biosidus S.A.、Bioton S.A.、Innovent Biologics, Inc.、JHL Biotech, Inc.、LG Chem, Ltd.、Merck Sharp & Dohme Corp.などの企業情報が含まれています。
・序論
・調査方法
・エグゼクティブサマリー
・市場概要
・市場インサイト
・世界のバイオシミラー市場規模:適応症別
- 自己免疫疾患における市場規模
- 血液疾患における市場規模
- 慢性疾患における市場規模
- 成長ホルモン欠乏症における市場規模
- その他おける市場規模
・世界のバイオシミラー市場規模:製品別
- 組換えグリコシル化タンパク質における市場規模
- 組換えペプチドにおける市場規模
・世界のバイオシミラー市場規模:製造別
- 受託製造における市場規模
- 自社製造における市場規模
・世界のバイオシミラー市場規模:地域別
- 南北アメリカのバイオシミラー市場規模
アメリカのバイオシミラー市場規模
カナダのバイオシミラー市場規模
ブラジルのバイオシミラー市場規模

- アジア太平洋のバイオシミラー市場規模
日本のバイオシミラー市場規模
中国のバイオシミラー市場規模
インドのバイオシミラー市場規模
韓国のバイオシミラー市場規模
台湾のバイオシミラー市場規模

- ヨーロッパ/中東/アフリカのバイオシミラー市場規模
イギリスのバイオシミラー市場規模
ドイツのバイオシミラー市場規模
フランスのバイオシミラー市場規模
ロシアのバイオシミラー市場規模

- その他地域のバイオシミラー市場規模
・競争状況
・企業情報

The Global Biosimilars Market size was estimated at USD 12.06 billion in 2021 and expected to reach USD 14.96 billion in 2022, and is projected to grow at a CAGR 24.18% to reach USD 44.27 billion by 2027.

Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:
This research report categorizes the Biosimilars to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Indication, the market was studied across Autoimmune Diseases, Blood Disorders, Chronic Diseases, Growth Hormone Deficiency, Infectious Diseases, and Oncology.

Based on Product, the market was studied across Recombinant Glycosylated Proteins, Recombinant Non-Glycosylated Proteins, and Recombinant Peptides. The Recombinant Glycosylated Proteins is further studied across Erythropoietin, Follitropin, and Monoclonal Antibodies. The Monoclonal Antibodies is further studied across Adalimumab, Infliximab, and Rituximab. The Recombinant Non-Glycosylated Proteins is further studied across Granulocyte Colony-Stimulating Factor, Insulin, Interferons, and Recombinant Human Growth Hormone. The Interferons is further studied across Interferon-Alpha and Interferon-Beta. The Recombinant Peptides is further studied across Calcitonin and Glucagon.

Based on Manufacturing, the market was studied across Contract Manufacturing and In-House Manufacturing.

Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Biosimilars market considering the current update on the conflict and its global response.

Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Biosimilars Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Biosimilars Market, including AMEGA Biotech S.A., Amgen Inc., Apotex Inc., Biosidus S.A., Bioton S.A., Innovent Biologics, Inc., JHL Biotech, Inc., LG Chem, Ltd., Merck Sharp & Dohme Corp., Mylan N.V., Pfizer Inc., and Sandoz International GmbH.

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:
1. What is the market size and forecast of the Global Biosimilars Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Biosimilars Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Biosimilars Market?
4. What is the competitive strategic window for opportunities in the Global Biosimilars Market?
5. What are the technology trends and regulatory frameworks in the Global Biosimilars Market?
6. What is the market share of the leading vendors in the Global Biosimilars Market?
7. What modes and strategic moves are considered suitable for entering the Global Biosimilars Market?

レポート目次

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing pressure to reduce healthcare expenditure
5.1.1.2. Growing demands of pharmaceutical drugs
5.1.1.3. Expiration of major patents during the forecast period
5.1.1.4. Supportive government initiative and awareness creating programs in the developing economies
5.1.1.5. Lower cost biosimilars drugs than original biologics
5.1.2. Restraints
5.1.2.1. Reluctance of physicians to prescribe biosimilars
5.1.2.2. Unawareness among patients and preference for brand
5.1.3. Opportunities
5.1.3.1. New indications and patent expiry of biologic products
5.1.3.2. Potential in emerging markets
5.1.3.3. Emergence of bio-betters drugs
5.1.4. Challenges
5.1.4.1. Stringent regulatory requirements adversely affecting investment in the biosimilars market
5.1.4.2. High investment required for research and development
5.2. Cumulative Impact of COVID-19

6. Biosimilars Market, by Indication
6.1. Introduction
6.2. Autoimmune Diseases
6.3. Blood Disorders
6.4. Chronic Diseases
6.5. Growth Hormone Deficiency
6.6. Infectious Diseases
6.7. Oncology

7. Biosimilars Market, by Product
7.1. Introduction
7.2. Recombinant Glycosylated Proteins
7.3.1. Erythropoietin
7.3.2. Follitropin
7.3.3. Monoclonal Antibodies
7.3.4.1. Adalimumab
7.3.4.2. Infliximab
7.3.4.3. Rituximab
7.3. Recombinant Non-Glycosylated Proteins
7.4.1. Granulocyte Colony-Stimulating Factor
7.4.2. Insulin
7.4.3. Interferons
7.4.4.1. Interferon-Alpha
7.4.4.2. Interferon-Beta
7.4.4. Recombinant Human Growth Hormone
7.4. Recombinant Peptides
7.5.1. Calcitonin
7.5.2. Glucagon

8. Biosimilars Market, by Manufacturing
8.1. Introduction
8.2. Contract Manufacturing
8.3. In-House Manufacturing

9. Americas Biosimilars Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Biosimilars Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Biosimilars Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion

13. Company Usability Profiles
13.1. AMEGA Biotech S.A.
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. Amgen Inc.
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. Apotex Inc.
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. Biosidus S.A.
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. Bioton S.A.
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. Innovent Biologics, Inc.
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. JHL Biotech, Inc.
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. LG Chem, Ltd.
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. Merck Sharp & Dohme Corp.
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. Mylan N.V.
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. Pfizer Inc.
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. Sandoz International GmbH
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services

14. Appendix
14.1. Discussion Guide
14.2. License & Pricing




• 英文レポート名:Biosimilars Market Research Report by Indication, Product, Manufacturing, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19
• 日本語訳:バイオシミラーの世界市場予測(~2027年)
• レポートコード:MRC2301G186お問い合わせ(見積依頼・ご注文・質問)